These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32823854)

  • 1. Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine.
    Mester-Tonczar J; Winkler J; Einzinger P; Hasimbegovic E; Kastner N; Lukovic D; Zlabinger K; Spannbauer A; Traxler D; Batkai S; Thum T; Gyöngyösi M
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32823854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
    Schimmel K; Jung M; Foinquinos A; José GS; Beaumont J; Bock K; Grote-Levi L; Xiao K; Bär C; Pfanne A; Just A; Zimmer K; Ngoy S; López B; Ravassa S; Samolovac S; Janssen-Peters H; Remke J; Scherf K; Dangwal S; Piccoli MT; Kleemiss F; Kreutzer FP; Kenneweg F; Leonardy J; Hobuß L; Santer L; Do QT; Geffers R; Braesen JH; Schmitz J; Brandenberger C; Müller DN; Wilck N; Kaever V; Bähre H; Batkai S; Fiedler J; Alexander KM; Wertheim BM; Fisch S; Liao R; Diez J; González A; Thum T
    Circulation; 2020 Mar; 141(9):751-767. PubMed ID: 31948273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study.
    Otterstad JE; Lubsen K; Parker A; Kirwan B; Plappert T; St John Sutton MG
    Scand Cardiovasc J; 1999; 33(4):234-41. PubMed ID: 10517211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine.
    Techiryan G; Weil BR; Palka BA; Canty JM
    Circ Res; 2018 Sep; 123(8):986-995. PubMed ID: 30355033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction.
    Ellmers LJ; Scott NJ; Cameron VA; Richards AM; Rademaker MT
    J Cardiovasc Pharmacol; 2015 Mar; 65(3):269-75. PubMed ID: 25658462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway.
    Wei X; Lv Y; Yang C; Gao R; Zou S; Xu Y
    Clin Exp Pharmacol Physiol; 2023 Aug; 50(8):688-697. PubMed ID: 37243403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lycorine ameliorates isoproterenol-induced cardiac dysfunction mainly via inhibiting inflammation, fibrosis, oxidative stress and apoptosis.
    Wu J; Fu Y; Wu YX; Wu ZX; Wang ZH; Li P
    Bioengineered; 2021 Dec; 12(1):5583-5594. PubMed ID: 34515620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.
    Milliez P; Messaoudi S; Nehme J; Rodriguez C; Samuel JL; Delcayre C
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H435-41. PubMed ID: 19074674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive cardiac phenotyping in large animals: comparison of pressure-volume analysis and cardiac magnetic resonance imaging in pig post-myocardial infarction systolic heart failure.
    Raake PWJ; Barthelmes J; Krautz B; Buss S; Huditz R; Schlegel P; Weber C; Stangassinger M; Haberkorn U; Katus HA; Most P; Pleger ST
    Int J Cardiovasc Imaging; 2019 Sep; 35(9):1691-1699. PubMed ID: 31056718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target.
    Schimmel K; Ichimura K; Reddy S; Haddad F; Spiekerkoetter E
    Front Cardiovasc Med; 2022; 9():886553. PubMed ID: 35600469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion.
    Tarkia M; Stark C; Haavisto M; Kentala R; Vähäsilta T; Savunen T; Strandberg M; Saunavaara V; Tolvanen T; Teräs M; Pietilä M; Nyman L; Duvall E; Saukko P; Levijoki J; Roivainen A; Saraste A; Knuuti J
    Heart; 2016 Mar; 102(6):465-71. PubMed ID: 26762238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction.
    Horiuchi Y; Tanimoto S; Aoki J; Nakajima H; Hara K; Tanabe K
    Int J Cardiol; 2016 Oct; 221():765-9. PubMed ID: 27428318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new model of congestive heart failure in rats.
    Chen J; Chemaly ER; Liang LF; LaRocca TJ; Yaniz-Galende E; Hajjar RJ
    Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H994-1003. PubMed ID: 21685270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Circular RNA Cdr1as Promotes Myocardial Infarction by Mediating the Regulation of miR-7a on Its Target Genes Expression.
    Geng HH; Li R; Su YM; Xiao J; Pan M; Cai XX; Ji XP
    PLoS One; 2016; 11(3):e0151753. PubMed ID: 26998750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
    Weir RA; Miller AM; Murphy GE; Clements S; Steedman T; Connell JM; McInnes IB; Dargie HJ; McMurray JJ
    J Am Coll Cardiol; 2010 Jan; 55(3):243-50. PubMed ID: 20117403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of anti-fibrotic natural compound similars with improved effectivity.
    Kreutzer FP; Meinecke A; Mitzka S; Hunkler HJ; Hobuß L; Abbas N; Geffers R; Weusthoff J; Xiao K; Jonigk DD; Fiedler J; Thum T
    Basic Res Cardiol; 2022 Mar; 117(1):9. PubMed ID: 35235052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
    Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
    Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac-specific deletion of SOCS-3 prevents development of left ventricular remodeling after acute myocardial infarction.
    Oba T; Yasukawa H; Hoshijima M; Sasaki K; Futamata N; Fukui D; Mawatari K; Nagata T; Kyogoku S; Ohshima H; Minami T; Nakamura K; Kang D; Yajima T; Knowlton KU; Imaizumi T
    J Am Coll Cardiol; 2012 Feb; 59(9):838-52. PubMed ID: 22361405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.